耳鼻咽喉科・頭頸部外科90巻3号

2018年03月発行

特集 頭頸部癌に対する薬物療法—最新情報

薬物同時併用放射線療法

著者： 横田知哉¹

所属機関： ¹静岡県立静岡がんセンター消化器内科

ページ範囲：P.212 - P.218

文献概要

POINT

●局所進行頭頸部癌に対する非外科的標準治療は，CDDPを併用する化学放射線療法である。

●局所進行頭頸部癌に対する治療オプションとして，セツキシマブ併用放射線療法がある。

●化学放射線療法に対するセツキシマブ併用放射線療法の非劣性は示されておらず，両者の使い分けに関して明らかなコンセンサスは得られていない。

●免疫チェックポイント阻害薬と放射線治療との併用療法が開発中である。

参考文献

1）Baujat B, et al：MAC-NPC Collaborative Group. Chemotherapy in locally advanced nasopharyngeal carcinoma：an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64：47-56, 2006

2）Zhang L, et al：The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population：a meta-analysis of the phase Ⅲ randomized trials. BMC Cancer 10：558, 2010

3）Chen QY, et al：Concurrent chemoradiotherapy vs radiotherapy alone in stage Ⅱ nasopharyngeal carcinoma：phase Ⅲ randomized trial. J Natl Cancer Inst 103：1761-1770, 2011

4）Nguyen-Tan PF, et al：Randomized phase Ⅲ trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial：long-term report of efficacy and toxicity. J Clin Oncol 32：3858-3866, 2014

5）Loong HH, et al：Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiother Oncol 104：300-304, 2012

6）Hamauchi S et al：Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin. Jpn J Clin Oncol 45：1116-1121, 2015

7）Forastiere AA, et al：Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349：2091-2098, 2003

8）Forastiere AA, et al：Long-term results of RTOG 91-11：a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31：845-852, 2013

9）Adelstein DJ, et al：An intergroup phase Ⅲ comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21：92-98, 2003

10）Pignon JP, et al：Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma：three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355：949-955, 2000

11）Pignon JP, et al：MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer（MACH-NC）：an update on 93 randomised trials and 17, 346 patients. Radiother Oncol 92：4-14, 2009

12）Egloff AM, et al：Epidermal growth factor receptor-targeted molecular therapeutics for head and neck squamous cell carcinoma. Expert Opin Ther Targets 10：639-647, 2006

13）Chung CH, et al：Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24：4170-4176, 2006

14）Bissada E, et al：Prevalence of K-RAS Codons 12 and 13 Mutations in Locally Advanced Head and Neck Squamous Cell Carcinoma and Impact on Clinical Outcomes. Int J Otolaryngol 2013：848021, 2013

15）Chen DJ, et al：The epidermal growth factor receptor：a role in repair of radiation-induced DNA damage. Clin Cancer Res 13：6555-6560, 2007

16）Dittmann K, et al：Inhibition of radiation-induced EGFR nuclear import by C225（Cetuximab）suppresses DNA-PK activity. Radiother Oncol 76：157-161, 2005

17）Bonner JA, et al：Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354：567-578, 2006

18）Ang KK, et al：Randomized Phase Ⅲ Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage Ⅲ to Ⅳ Head and Neck Carcinoma：RTOG 0522. J Clin Oncol. 2014 Aug 25. pii：JCO. 2013.53.5633

19）Giralt J, et al：Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck（CONCERT-2）：a randomised, controlled, open-label phase 2 trial. Lancet Oncol 16：221-232, 2015

20）Siu LL, et al：Effect of Standard radiotherapy with cisplatin vs accelerated radiotherapy with panitumumab in locoregionally advanced squamous cell head and neck carcinoma：a randomized clinical trial. JAMA Oncol. 2016 Dec 8. doi：10.1001/jamaoncol.2016.4510

21）Magrini SM, et al：Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer：a randomized Phase Ⅱ trial. J Clin Oncol 34：427-435, 2016

22）Lefebvre JL, et al：Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation the TREMPLIN randomized phase Ⅱ study. J Clin Oncol 31：853-859, 2013

23）Hitt R, et al：Randomized phase Ⅲ trial of induction chemotherapy（ICT）with docetaxel-cisplatin-5fluorouracil（DCF）followed by cisplatin-radiotherapy（CRT）or cetuximab-radiotherapy（CetRT）in patients（pts）with locally advanced unresectable head and neck cancer（LAUHNC）. J Clin Oncol 34 suppl：6001-6001, 2016

24）Salama AK, et al：Irradiation and immunotherapy：From concept to the clinic. Cancer 122：1659-1671, 2016

25）Deng L, et al：Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 124：687-695, 2014

26）Qin X, et al：Cisplatin induces programmed death-1-ligand 1（PD-L1）over-expression in hepatoma H22 cells via Erk/MAPK signaling pathway. Cell Mol Biol（Noisy-le-grand） 56 Suppl：OL1366-1372, 2010

27）Mouw KW, et al：DNA Damage and repair biomarkers of immunotherapy response. Cancer Discov 7：675-693, 2017

28）Reynders K, et al：The abscopal effect of local radiotherapy：using immunotherapy to make a rare event clinically relevant. immunologic responses to localized irradiation are proposed as mediator of systemic effects after localized radiotherapy. Cancer Treat Rev 41：503-510, 2015

29）Powell SF, et al：Safety of pembrolizumab with chemoradiation（CRT）in locally advanced squamous cell carcinoma of the head and neck（LA-SCCHN）. J Clin Oncol 35 suppl：6011-6011, 2017

30）Ferris RL et al：Phase Ⅰ trial of cetuximab, intensity modulated radiotherapy（IMRT）, and ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma（PULA HNSCC）. 1057P ESMO2017

31）Antonia SJ, et al：Durvalumab after Chemoradiotherapy in Stage Ⅲ Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Sep 8. doi：10.1056/NEJMoa1709937